Article
In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.
Clinical pharmacology and therapeutics - 1 Sept 2011
de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers D R J
Abstract excerpt
In vitro studies have identified cyclosporine and tacrolimus as CYP3A inhibitors. In the current study in renal allograft recipients, we used intravenously and orally administered midazolam as a drug probe to assess whether the study drugs at doses that are generally used in clinical practice have differential effects on in vivo hepatic and first-pass CYP3A activities. Systemic and apparent oral midazolam...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.